ArticleScientific reports2026
Adapalene, an RAR agonist, exerts anti-inflammatory effects by regulating macrophage polarization through RAR[Formula: see text]-mediated signaling pathways.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Retinoic acid receptor (RAR) is a nuclear receptor that plays a critical role in regulating cellular proliferation and differentiation through transcriptional control. However, its role in the macrophage inflammatory response remains poorly understood. In the present study, we explored the effects of adapalene, a selective RARβ and RARγ agonist, on lipopolysaccharide (LPS)-induced inflammation in RAW264.7 cells. Adapalene inhibited the LPS-induced inflammatory response in a concentration-dependent manner, whereas the anti-inflammatory effects of adapalene were attenuated by RARβ-targeting small interfering RNA (siRNA) or an RARβ antagonist (LE135). Mechanistic investigations revealed that adapalene suppressed LPS-induced phosphorylation of the MAPK and PI3K/Akt pathways, thereby inhibiting the nuclear translocation of NF-κB in RAW264.7 cells. In addition, adapalene upregulated the expression of anti-inflammatory M2 macrophage markers, accompanied by increased STAT3 phosphorylation. The acute administration of adapalene to C57BL/6J mice protected against LPS-induced inflammation, liver damage, and septic shock-related mortality in vivo. Furthermore, chronic oral administration of adapalene in high-fat diet (HFD)-induced obese mice reduced pro-inflammatory markers while increasing anti-inflammatory markers in the liver. These findings suggest that adapalene exerts potent anti-inflammatory effects in macrophages through RARβ activation, thus highlighting its potential as a therapeutic agent for treating inflammatory and metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.